What we’re looking forward to at the 2016 340B Winter Conference

Every winter 340B Health  brings key healthcare stakeholders together to discuss new 340B program developments, brainstorm and network at the 340B Coalition Winter Conference.  This event provides a terrific forum for education, discussion and insight into what’s working well with the program and where there are opportunities for improvement. As a leader in personalized medication… read more

What’s Missing: J.P. Morgan Healthcare Conference 2016

The J.P. Morgan Healthcare Conference 2016 will arguably rank as the largest business of healthcare conference scheduled anywhere in the world this year. Although there have already been numerous reviews and takeaways regarding the conference, I’d like to share with you the top three topics absent from this year’s conference. What is the most needed that we didn’t… read more

Building a Better Patient Journey

Curant’s Managing Director of Operations, Dave Cunnold, is featured in Managed Healthcare Executive providing insight on the evolution of the healthcare experience for patients with chronic conditions. The successful patient journey has evolved due to the transition to value-based care and the need to drive better health outcomes. What works now is an approach that is… read more

Who’s ready to go “at risk” and win at the JP Morgan Healthcare Conference 2016?

Every year, the business of healthcare gathers en mass at the annual J.P. Morgan Healthcare Conference. What will we learn? What will we hear? What will be missing? Sadly, I do not believe we will learn or hear anything of substance, especially when it comes to patient care. This conference is about the healthcare business,… read more

Three things more presidential than bashing pharmaceutical manufacturers

Curant COO, Marc O’Connor, was recently featured in Specialty Pharmacy Times in a piece that highlights the futility of presidential candidates focusing strictly on pharmaceutical manufacturers as the primary source of healthcare’s woes. It is true that companies such as Turing Pharmaceutical have the ability to cause a strong negative domino effect on patients with pricing… read more

Treating an HIV and Hepatitis C Co-infection Takes Therapies, Adherence and Hope

Being diagnosed with an illness such as hepatitis C can be shocking for some, to say the least. Receiving a diagnosis of HIV and hepatitis C co-infection can be life-altering. According to the Centers for Disease Control and Prevention (CDC): 25% of patients living with HIV in the U.S. are co-infected with hepatitis C 80% of… read more

Media contact: Kristin Lindsey, Marketing Director at 866-437-8040, extension 253 or klindsey@curanthealth.com

 
EmailEmailEmailEmail
Menu Title